» Articles » PMID: 30872574

Extracellular Vesicle-based Therapeutics: Natural Versus Engineered Targeting and Trafficking

Overview
Journal Exp Mol Med
Date 2019 Mar 16
PMID 30872574
Citations 326
Authors
Affiliations
Soon will be listed here.
Abstract

Extracellular vesicles (EVs) are increasingly being recognized as mediators of intercellular signaling via the delivery of effector molecules. Interestingly, certain types of EVs are also capable of inducing therapeutic responses. For these reasons, the therapeutic potential of EVs is a topic of intense research, both in the context of drug delivery and regenerative medicine. However, to fully utilize EVs for therapeutic purposes, an improved understanding of the mechanisms by which they function would be highly advantageous. Here, the current state of knowledge regarding the cellular uptake and trafficking of EVs is reviewed, along with a consideration of how these pathways potentially influence the functions of therapeutic EVs. Furthermore, the natural cell-targeting abilities, biodistribution profiles, and pharmacokinetics of exogenously administered EVs, along with the components responsible for these features are discussed. An overview of the potential clinical applications and preclinical examples of their successful use is also provided. Finally, examples of EV modifications that have successfully been employed to improve their therapeutic characteristics receive a particular focus. We suggest that, in addition to investigation of EV cell targeting and routes of uptake, future research into the routes of intracellular trafficking in recipient cells is required to optimally utilize EVs for therapeutic purposes.

Citing Articles

Porcine milk small extracellular vesicles modulate peripheral blood mononuclear cell proteome in vitro.

Avila G, Bonnet M, Viala D, Dejean S, Agazzi A, Lecchi C Sci Rep. 2025; 15(1):8069.

PMID: 40055486 PMC: 11889182. DOI: 10.1038/s41598-025-92550-3.


Extracellular vesicles of SLAM216 ameliorate skin symptoms of atopic dermatitis by regulating gut microbiome on serotonin metabolism.

Choi H, Kwak M, Choi Y, Kang A, Mun D, Eor J Gut Microbes. 2025; 17(1):2474256.

PMID: 40028723 PMC: 11881872. DOI: 10.1080/19490976.2025.2474256.


Development of a cell-penetrating peptide-based nanocomplex for long-term delivery of intact mitochondrial DNA into epithelial cells.

Wilson K, Holjencin C, Lee H, Annamalai B, Ishii M, Gilbert J Mol Ther Nucleic Acids. 2025; 36(1):102449.

PMID: 39991470 PMC: 11847061. DOI: 10.1016/j.omtn.2025.102449.


CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations.

Lee H, Rho W, Kim Y, Chang H, Jun B Molecules. 2025; 30(3).

PMID: 39942646 PMC: 11820414. DOI: 10.3390/molecules30030542.


CD9-enriched extracellular vesicles from chemically reprogrammed basal progenitors of salivary glands mitigate salivary gland fibrosis.

Park S, Yoon Y, Hong Y, Yu J, Cho J, Jeong Y Bioact Mater. 2025; 47:229-247.

PMID: 39925710 PMC: 11803853. DOI: 10.1016/j.bioactmat.2025.01.019.


References
1.
Janzarik H, Lasch H . [Plasma substitutes in acute blood loss of the rabbit]. Helv Chir Acta. 1966; 33(3):392-403. View

2.
van Niel G, DAngelo G, Raposo G . Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018; 19(4):213-228. DOI: 10.1038/nrm.2017.125. View

3.
Roth N, Schwolow R, Gille H . Psychophysiological assessment of transcutaneous electric nerve stimulation (TENS) effects upon orofacial pain. Biomed Biochim Acta. 1990; 49(7):613-8. View

4.
Narita T, Suto K, Kodate C, Kudo H . Glycogen storage disease associated with Niemann-Pick disease. N Engl J Med. 1989; 320(12):810-1. View

5.
DORTA T . [Practical experience with liver scintigraphy]. Schweiz Med Wochenschr. 1968; 98(8):290-2. View